Blemaren, 80 pcs.

When dissolving fizzy tablets Blemaren® in water, potassium sodium hydrocitrate and carbon dioxide are formed. When taking the drug, the pH of the urine increases.

Thus, the drug dissolves and prevents the formation of uric acid stones.

In addition, it increases citrate excretion and decreases calcium excretion, improves solubility of calcium oxalate in the urine, inhibits crystal formation and, therefore, prevents the formation of calcium-oxalate stones.

Bioavailability – about 100%. After a day of taking the preparation Blemaren® the administered amount of sodium and potassium is excreted from the body through the kidneys during 24-48 hours.

During long-term use of the drug daily excretion of potassium and sodium corresponds to the daily intake. In blood or plasma no significant changes in blood gases or electrolytes are noted.

This means that due to renal regulation of alkalinization acid-alkaline balance in the body is maintained, and accumulation of sodium and potassium with normal renal function does not occur.

Indications

Dissolution of uric acid and calcium oxalate stones in the urinary tract, preventing their formation;
dissolution of mixed uric acid-oxalate stones (with an oxalate content of less than 25%)
alkalinization of urine in persons receiving cytostatics or drugs that increase the excretion of uric acid; when treating patients with cystine stones;
symptomatic treatment of skin porphyria

Pharmacological effect

When Blemaren® effervescent tablets are dissolved in water, potassium-sodium hydrocitrate and carbon dioxide are formed. When taking the drug, the urine pH increases.

Thus, the drug dissolves and prevents the formation of uric acid stones.

In addition, it enhances the excretion of citrates and reduces the excretion of calcium, improves the solubility of calcium oxalate in urine, inhibits the formation of crystals and, therefore, prevents the formation of calcium oxalate stones.

Bioavailability is about 100%. After a one-day dose of Blemaren®, the administered amount of sodium and potassium is excreted from the body by the kidneys within 24 to 48 hours.

With prolonged use of the drug, the daily excretion of potassium and sodium corresponds to the daily intake. There are no significant changes in blood gases or electrolytes in the blood or plasma.

This means that due to the renal regulation of alkalization, the acid-base balance in the body is maintained, and the accumulation of sodium and potassium does not occur with normal kidney function.

Special instructions

The average daily dose (4 effervescent tablets) contains about 1.5 mg of potassium and 0.9 g of sodium (should be taken into account in patients with limited salt intake).

Can be used for chronic renal failure not accompanied by potassium ion retention.

Can be prescribed to patients with diabetes.

When dissolving uric acid stones, one should not allow many days of excessive alkalization of urine, since with an increase in pH above 7.8, a precipitate of phosphate soda may appear on the surface of uric acid crystals, which may prevent their further dissolution.

During treatment, you should limit your intake of foods rich in proteins and purine bases, and ensure sufficient fluid intake (at least 1.5-2 liters).

Active ingredient

Potassium bicarbonate, Citric acid, Sodium citrate

Composition

1 effervescent tablet contains:

active ingredients:

anhydrous citric acid – 1197.0 mg,

potassium bicarbonate – 967.5 mg,

sodium citrate anhydrous – 835.5 mg;

excipients:

Pregnancy

There is no confirmed data on the undesirable effects of the drug Blemaren® during pregnancy and breastfeeding. The drug can be taken after consultation with a doctor.

Contraindications

Hypersensitivity;
lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
acute and chronic renal failure;
metabolic alkalosis;
urinary tract infections caused by microorganisms that break down urea;
episodic hereditary adynamia;
the need to adhere to a strict salt-free diet (for example, in severe forms of arterial hypertension);
children under 12 years of age (since there is not enough clinical experience regarding this age group).

Side Effects

According to the World Health Organization (WHO), adverse effects are classified according to their frequency as follows: very common (> 1/10), common (> 1/100, 1/1000, 1/10000, <1/1000) and very rare (<1/10000); frequency unknown (the frequency of events cannot be determined from available data).In case of individual intolerance to the components of the drug, allergic reactions are possible.From the gastrointestinal tract: often – pain in the abdomen, nausea, vomiting, diarrhea.Metabolism and nutrition: frequency unknown – edema (sodium retention), metabolic alkalosis.

Interaction

Concomitant use of drugs containing citrates and aluminum may lead to increased absorption of aluminum. The interval between doses of such drugs should be at least 2 hours.

The effect of cardiac glycosides may be weakened when administered simultaneously with the drug Blemaren®, due to the presence of potassium in the drug.

Some drugs that lower blood pressure (aldosterone antagonists, potassium-sparing diuretics, angiotensin-converting enzyme blockers, sartans), as well as non-steroidal anti-inflammatory drugs and analgesics may reduce potassium excretion.

Overdose

With normal renal function, no undesirable effect of the drug on changes in physiological metabolic parameters was noted either at the usual recommended dose or at a higher one, since the release of excess alkalis by the kidneys is a natural mechanism for regulating the acid-base balance in the body.

The upper limit of the urine pH range stated above should not be exceeded for several days, as there is an increased risk of phosphate crystallization due to increased pH (pH > 7.8).

A possible overdose can be corrected by reducing the dose of the drug. If necessary, measures can be taken to treat metabolic alkalosis.

Storage conditions

Store out of the reach of children at a temperature not exceeding 25°C.
After opening, keep away from moisture!

Shelf life

4 years.

Manufacturer

Laboratorios Medicamentos Internationales, S.A., Spain